Trials / Completed
CompletedNCT05731908
A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems
Pharmacokinetics, Safety, and Tolerability of BI 690517 in Subjects With Mild and Moderate Liver Impairment (Child-Pugh Classification A and B) as Compared to Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The main objective of this trial is to assess the effect of mild and moderate hepatic impairment (Child-Pugh classification A and B) on the pharmacokinetics, safety, and tolerability of BI 690517 in comparison with a control group with normal hepatic function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 690517 | BI 690517 |
Timeline
- Start date
- 2023-02-21
- Primary completion
- 2023-04-13
- Completion
- 2023-04-13
- First posted
- 2023-02-16
- Last updated
- 2024-09-20
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05731908. Inclusion in this directory is not an endorsement.